Heal in India

09/11/2020

How The Treatment Works: Mechanism Of Action for LU177 PRRT for Neuroendocrine Tumors(NETS).

14/09/2020

The month of September is recognized as Prostate Cancer Awareness Month. At the Department of Nuclear Medicine at Fortis Memorial Research Institute (FMRI), Gurugram, India, the team of nuclear oncology experts have dedicated themselves to treat and control the spread of the disease. It is the only centre in India that offers Alpha PSMA Therapy for Metastatic Castration Resistant Prostate Cancer (mCRPC) patients. The therapy provides a new ray of hope for prostate cancer patients.

16/07/2020

For advanced prostate cancer patients or metastatic castration-resistant prostate cancer (mCRPC) patients, conventional treatment modalities, such as surgery, chemotherapy etc. might not prove to be highly effective in terms of controlling the spread of the cancer. This is where Nuclear Medicine and Molecular Imaging are playing an important part in the management of cancer and that too in a personalized manner.

Read More at https://nuclearmedicinetherapy.in/blog/225ac-psma-617-a-new-beginning-in-the-treatment-of-chemotherapy-naive-prostate-cancer-patients

10/07/2020

Alpha PSMA Therapy in Prostate Cancer Treatment

Several nuclear medicine clinics around the world have confirmed that Targeted Alpha Therapy (TAT) or Alpha PSMA Therapy using radiolabeled PSMA inhibitors, has the potential to bring about a paradigm shift in the treatment of metastatic castration resistant prostate cancer (mCRPCa) patients.

Targeted Alpha Therapy or Alpha PSMA Therapy is a targeted, selective internal medicine cellular level radiotherapy used to control advanced prostate and prostate cancer.

22/06/2020

Research has shown that in men with metastatic castration-resistant prostate cancer who have progressed after conventional therapies, Radionuclide Treatment with Lu177 PSMA-617 not only has high response rates, low toxic effects, but most importantly reduced pain - by the second cycle of treatment, patients experienced a ten point or more improvement in global health score.

For more information on the efficacy of Lutetium 177 PSMA Therapy do call us at +91 98111 27080, or write to us at info@nuclearmedicinetherapy.in or visit https://nuclearmedicinetherapy.in/treatments/lu-psma-therapy

15/06/2020

Research has shown that in men with metastatic castration-resistant prostate cancer who have progressed after conventional therapies, Lu177 PSMA Therapy not only has high response rates, low toxic effects, but most importantly reduced pain.

For more information on the efficacy of Lutetium 177 PSMA Therapy do call us at +91 9811127080, or write to us at info@nuclearmedicinetherapy.in or visit https://nuclearmedicinetherapy.in/Treatments/Lu-PSMA-Therapy

15/06/2020

Several studies and clinical trials have shown that men with advanced prostate cancer have responded extremely well to Lu177 PSMA – reduced pain, shrunk tumours, and rapid relief from bone pain, thereby leaving them with more energy to enjoy family time.

For more information on the efficacy of Lutetium 177 PSMA Therapy do call us at +91 98111 27080, or write to us at info@nuclearmedicinetherapy.in or visit https://nuclearmedicinetherapy.in/treatments/lu-psma-therapy

22/05/2020

Transarterial Radioembolization (TARE), is an emerging and promising therapy for the treatment of all stages of hepatocellular carcinoma (from intermediate to advanced). And when compared to standard radiation therapy, TARE has fewer side-effects.

For more information on TARE do call us at +91 98111 27080, or write to us at info@nuclearmedicinetherapy.in or visit https://nuclearmedicinetherapy.in/treatments/transarterial-radioembolisation